Trace Neuroscience, a biopharmaceutical launch based in South San Francisco, is targeting the UNC13A protein as a possible treatment path for amyotrophic lateral sclerosis (ALS) and other neurogenerative diseases. In a Nov. 12 press release, the company said UNC13A “is a genetically validated target with the potential to treat 97% of people living with ALS.”…